Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Abivax raised $920 million in its latest funding round, providing capital to support operations through 2029, according to the company's CEO in an interview with CNBC. The French biotech company plans to use the funds to conduct a U.S. product launch independently rather than pursuing a partnership or acquisition. The funding amount and timeline were disclosed directly by the CEO to CNBC.

Next story